Immune checkpoint inhibitors have appeared to be effective in the treatment of cancer. Genetic engineering techniques enable researchers to develop humanized mouse models that can interact with humanized antibodies to CTLA4 or PD1. Greentech Bioscience currently provides you with validated humanized mouse models for immune checkpoint models, including humanized PD-1 mouse model and humanized CTLA-4 mouse model for preclinical testing of novel immune checkpoint targeted therapies.
Programmed cell death-1 (PD-1) plays an imperative part in inhibiting immune responses and advancing self-tolerance. The hPD-1 mouse model provides a tool for pre-clinical screening and efficacy evaluation of immune-oncology therapies targeting PD-1 in fully immunocompetent mice.
Cytotoxic T-lymphocyte-associated protein 4 (CTLA4, also known as CD152) acts as an immune checkpoint. Humanized CTLA-4 mice are developed through transgenic technologies, enabling preclinical testing of cancer immunotherapy and other applications.
Induction: subcutaneous/orthotopic injection of tumor cells
MC38 subcutaneous xenograft model (C57BL/6-hPD-1 mice)
Du X, Liu M, Su J, et al. Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice[J]. Cell research, 2018, 28(4): 433-447.